EdiGene | Genome Editing for a Better Life

Genome Editing for a Better Life

Four Genome Editing Based Platforms

Our Pipeline
Ex vivo and in vivo gene-editing therapies,
and targeted therapies

Patient focused

Genetic diseases

Cancer

News

Press Releases

EdiGene to Present Data on its Lead RNA Base Editing Program to Treat Patients w ...

Read More》

Press Releases

EdiGene and Immunochina Announce Research and Development Collaboration to Develop Allogeneic CAR-T Therapy for Cancer

Read More》
Press Releases

EdiGene to Present Data on Manufacturing Scale-up and Preclinical Development of its Leading Gene Editing Therapeutic Program to Treat Patients with β-Thalassemia Major

Read More》
Press Releases

Genome Editing Biotech EdiGene Raises $11 M in Series Pre-B2 Financing and Forms Research Collaboration to Develop Allogeneic T-cell Therapeutics for Cancer

Read More》
Press Releases

Abcam Enters Cell Editing Market Through Acquisition of EdiGene’s Knock-out Cell Lines and Lysates Portfolio

Read More》

Follow us on WeChat

Contact Us

Careers : hr@EdiGene.com
Partnership : bd@EdiGene.com
Media Inquiries : media@EdiGene.com

About Us

Company Overview Scientific Founder Leadership Contact Us

Our Business

Gene Editing Our Pipeline Our Focus

News

Press Releases In the Media

Careers

Join Us

Copyright © 2020 EdiGene Inc. All Rights Reserved.